Tag: PXL770
Poxel Obtains Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for PXL770 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) – 03/10/2022 at 07:30
• Preclinical studies have demonstrated the potential of PXL770 for Phase II development in the treatment of ADPKD • Efficacy data from preclinical studies confirm the interest of the strategic…
Poxel Obtains Orphan Drug Designation (ODD) from the FDA for PXL065 and PXL770
By Hector Chaunu Published on 05/17/2022 at 6:02 p.m. Photo credit © Reuters …